norfluoxetine has been researched along with Diabetes Mellitus, Type 1 in 1 studies
norfluoxetine: metabolite of fluoxetine; RN given refers to parent cpd without isomeric designation
Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Median effective dose was interpolated from the triplicated experiments and the dose-response curves were generated for each drug-virus combination." | 1.56 | A preclinical assessment to repurpose drugs to target type 1 diabetes-associated type B coxsackieviruses. ( Honkimaa, A; Hyöty, H; Sioofy-Khojine, AB, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sioofy-Khojine, AB | 1 |
| Honkimaa, A | 1 |
| Hyöty, H | 1 |
1 other study available for norfluoxetine and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
A preclinical assessment to repurpose drugs to target type 1 diabetes-associated type B coxsackieviruses.
Topics: A549 Cells; Amides; Antiviral Agents; Azithromycin; Benzimidazoles; Coxsackievirus Infections; Diabe | 2020 |